SM
XENE icon

Sabby Management’s Xenon Pharmaceuticals XENE Stock Holding History

Sabby Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-67,000
Closed -$328K – 186
2018
Q1 		$328K Sell
67,000
-262,400
-80% -$970K 0.04% 112
2017
Q4 		$931K Buy
329,400
+21,800
+7% +$59.3K 0.08% 76
2017
Q3 		$907K Sell
307,600
-3,208
-1% -$9.93K 0.06% 80
2017
Q2 		$979K Buy
310,808
+14,330
+5% +$56K 0.06% 102
2017
Q1 		$1.19M Buy
+296,478
New +$2.33M 0.06% 123

Other funds holding XENE

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Sabby Management's XENE Position: Q2 2018 in Review

Sabby Management sold out of Xenon Pharmaceuticals (XENE) in Q2 2018, closing a stake of 67,000 shares — an estimated $328K sold.

Sabby Management first reported a position in XENE in Q1 2017 and held it in 5 quarters. The position peaked at $1.19M in Q1 2017. 42 funds tracked by Wall St. Rank hold XENE as of Q2 2018.

  • Sabby Management reported no remaining Xenon Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Sabby Management sold 67,000 Xenon Pharmaceuticals shares in Q2 2018, an estimated $328K.
  • Sabby Management first reported a position in Xenon Pharmaceuticals in Q1 2017 and held it in 5 quarters.
  • Sabby Management's Xenon Pharmaceuticals position peaked at $1.19M in Q1 2017.
  • 42 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2018.

Based on Sabby Management's 13F filing for Q2 2018, filed 14 Aug 2018.